A phase I trial to investigate MT-4019 in patients with multiple myeloma
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2018
Price : $35 *
At a glance
- Drugs MT-4019 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 09 Aug 2018 According to a Molecular Templates media release, the company anticipates filing an IND application for MT-4019 in 3Q18.
- 28 Mar 2018 Molecular Templates anticipates filing an IND application for MT-4019 in mid-2018 to initiate the Phase I trial in the United States in 2H 2018, according to a Molecular Templates media release.
- 10 Jan 2018 New trial record